TY - JOUR
T1 - The Chicago Consensus on peritoneal surface malignancies
T2 - Management of appendiceal neoplasms
AU - Chicago Consensus Working Group
AU - Schuitevoerder, Darryl
AU - Plana, Alejandro
AU - Izquierdo, Francisco J.
AU - Votanopoulos, Konstantinos I.
AU - Cusack, James C.
AU - Bijelic, Lana
AU - Cho, Clifford S.
AU - Gangi, Alexandra
AU - Gilbert, Erin W.
AU - Goodman, Martin D.
AU - Govindarajan, Anand
AU - Gushchin, Vadim
AU - Ihemelandu, Chukwuemeka
AU - Kelly, Kaitlyn J.
AU - Merkow, Ryan P.
AU - Pappas, Sam G.
AU - Abbott, Daniel E.
AU - Ahrendt, Steven A.
AU - Al-Kasspooles, Mazin
AU - Alpert, Lindsay
AU - Amersi, Farin
AU - Arrington, Amanda K.
AU - Badgwell, Brian
AU - Barone, Robert M.
AU - Baumgartner, Joel M.
AU - Blazer, Dan G.
AU - Berri, Richard N.
AU - Brown, Charles Komen
AU - Catenacci, Daniel V.
AU - Chan, Carlos H.F.
AU - Choudry, M. Haroon A.
AU - Clarke, Callisia N.
AU - Cloyd, Jordan M.
AU - Dachman, Abraham H.
AU - Deneve, Jeremiah L.
AU - Dineen, Sean P.
AU - Fernandez, Leopoldo J.
AU - Eng, Oliver S.
AU - Fleshman, James W.
AU - Gamblin, T. Clark
AU - Georgakis, Georgios V.
AU - Grotz, Travis E.
AU - Hanna, Nader
AU - Harmath, Carla
AU - Hart, John
AU - Hayes-Jordan, Andrea
AU - Husain, Aliya N.
AU - Idrees, Kamran
AU - In, Haejin
AU - Jiang, David
N1 - Funding Information:
Funded by the Irving Harris Foundation and the University of Chicago.
Funding Information:
James C. Cusack reports grants from Lumicell, Inc, outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and nonfinancial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, Bristol‐Myers Squibb, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, Bristol‐Myers Squibb, Deciphera, GlaxoSmithKline, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Chih‐Yi Liao reports personal fees from Eisai, Exelixis, and Klus Pharma outside the submitted work. Garrett M. Nash reports nonfinancial support from Intuitive outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. David P. Ryan reports personal fees from and equity in MPM Capital; equity in Acworth Pharmaceuticals; and personal fees from Oncorus, Gritstone Oncology, Maverick Therapeutics, TCR Therapeutics, UpToDate, McGraw‐Hill, and Johns Hopkins University Press, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The other authors made no disclosures. 2
Publisher Copyright:
© 2020 by the American Cancer Society and Society of Surgical Oncology
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
AB - The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
KW - appendiceal neoplasms
KW - consensus
KW - neoplasm metastasis
KW - peritoneal neoplasms
KW - pseudomyxoma peritonei
UR - http://www.scopus.com/inward/record.url?scp=85084594927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084594927&partnerID=8YFLogxK
U2 - 10.1002/cncr.32881
DO - 10.1002/cncr.32881
M3 - Article
C2 - 32282073
AN - SCOPUS:85084594927
VL - 126
SP - 2525
EP - 2533
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 11
ER -